Immunovant Inc is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for patients with autoimmune diseases. The company's lead product candidate, IMVT-1401, is a novel, fully human monoclonal antibody that targets the neonatal Fc receptor (FcRn) and is currently being evaluated for the treatment of several autoimmune diseases, including myasthenia gravis and thyroid eye disease. In addition, the company is developing IMVT-1203, a novel antibody-drug conjugate that targets the same receptor, for the treatment of certain cancers. Immunovant is headquartered in New York City and was founded in 2017.
Immunovant Inc is a clinical-stage biopharmaceutical company that focuses on developing innovative therapies for patients with autoimmune diseases. The company's lead product candidate, IMVT-1401, is a novel, fully human monoclonal antibody that targets the neonatal Fc receptor (FcRn) and is currently being evaluated for the treatment of several autoimmune diseases, including myasthenia gravis and thyroid eye disease. In addition, the company is developing IMVT-1203, a novel antibody-drug conjugate that targets the same receptor, for the treatment of certain cancers. Immunovant is headquartered in New York City and was founded in 2017.